provide evidence that a ceRNA-based SEC14L2/SLC6A1 axis has an impact on the changes in the tumor immune microenvironment and might be a novel important prognostic factor associated with the diagnosis and prognosis of HCC. This evidence concerns the gene SLC6A1 and hepatocellular carcinoma.